Pacira BioSciences, Inc. PCRX Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Collegium Pharmaceutical, Inc.COLL

——

Segments

By segment

See full

Reportable Segment-$2.28M+14.9%

Other financials

Income statement

See full

Revenue$177.4M+5.0%

Gross profit$141.0M+4.7%

Operating income$6.9M+247%

Net income$2.9M-39.4%

EPS (diluted)$0.07-30.0%

Balance sheet

See full

Cash & equivalents$144.3M-49.1%

Total debt$411.2M+15.3%

Total equity$653.9M-18.1%

Total assets$1.2B-23.8%

Cash flow

See full

Operating cash flow$25.7M-27.6%

CapEx$2.7M-68.1%

Free cash flow$23.0M-14.7%

Valuation

See full

Market cap$942.78M-14.5%

Enterprise value$1.21B+2.6%

P/E183.5×—

P/S1.3×-0.3×

Profitability

See full

Gross margin79.3%+1.7pp

Operating margin3.3%—

Net margin0.7%—

FCF margin18.1%-4.6pp

Returns & leverage

See full

Return on equity0.7%—

Debt / equity0.6×+0.2×

Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s contingent consideration fair value adjustments?: Pacira BioSciences, Inc. (PCRX) reported contingent consideration fair value adjustments of -$2.28M in Q1 2026.
How has Pacira BioSciences, Inc.'s contingent consideration fair value adjustments changed year-over-year?: Pacira BioSciences, Inc.'s contingent consideration fair value adjustments increased by 14.9% year-over-year, from -$2.68M to -$2.28M.